Table of Contents 3
List of Tables 5
List of Figures 5
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Proteostasis Therapeutics Raises USD37 Million in Series B Financing 12
Proteostasis Therapeutics Raises USD22 Million in Venture Financing 14
Proteostasis Therapeutics Raises Additional USD2 Million in Venture Financing 15
Proteostasis Therapeutics Raises USD3 Million in Venture Financing 16
Partnerships 17
Basilea Pharma Enters into Agreement with Adult Brain Tumor Consortium 17
Basilea Pharmaceutica International Enters into Agreement with Biomedical Advanced Research and Development Authority 18
Proteostasis Therapeutics Amends Research Agreement with Astellas Pharma 19
Proteostasis Therapeutics Extends Co-Development Agreement With Cystic Fibrosis Foundation Therapeutics 20
Proteostasis Therapeutics Enters Into Co-Development Agreement With Scripps Research Institute 21
Proteostasis Therapeutics Enters into Co-Development Agreement with Cystic Fibrosis Foundation Therapeutics 22
Licensing Agreements 23
Grupo Biotoscana Enters into Licensing Agreement with Basilea Pharma 23
Basilea Pharma Enters into Licensing Agreement with Asahi Kasei Pharma 24
Hikma Pharma Extends its Distribution Agreement with Basilea Pharma 25
Basilea Pharmaceutical Amends Terms of Licensing Agreement with Stiefel Labs for Toctino 26
Dotmatics Enters Into Licensing Agreement With Basilea Pharma For Pre-Clinical Research Informatics 27
Equity Offering 28
Proteostasis Therapeutics Prices Public Offering of Shares for USD74.3 Million 28
Proteostasis Therapeutics to Raise USD50 Million in Public Offering of Shares 30
Proteostasis Therapeutics Withdraws Public Offering of Shares for USD65.6 Million 31
Proteostasis Therapeutics Raises USD46 Million in Public Offering of Shares 33
Proteostasis Therapeutics Raises USD65 Million in Public Offering of Shares 35
Proteostasis Therapeutics Inc - Key Competitors 37
Proteostasis Therapeutics Inc - Key Employees 38
Proteostasis Therapeutics Inc - Locations And Subsidiaries 39
Head Office 39
Recent Developments 40
Financial Announcements 40
Mar 14, 2018: Proteostasis Therapeutics Announces Fourth Quarter and Year-End 2017 Financial Results 40
Nov 14, 2017: Proteostasis Therapeutics Reports Third Quarter 2017 Results and Provides CF Portfolio Update 43
Mar 30, 2017: Proteostasis Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update 45
Corporate Communications 47
Jul 31, 2017: Proteostasis Appoints Helen M. Boudreau as Chief Financial Officer 47
Feb 27, 2017: Basilea proposes Dr. Nicole Onetto as new member of the Board of Directors 48
Product News 49
12/11/2017: Proteostasis Therapeutics Announces Positive Clinical Results from Studies of PTI-801 in Healthy Volunteers and Patients with Cystic Fibrosis 49
Oct 31, 2017: Proteostasis Therapeutics Focuses on Research and Development of CF Drug Candidates and Astellas Pharma Collaboration Programs 50
07/31/2017: Proteostasis Therapeutics Provides Update on Development of PTI-428 51
07/31/2017: Proteostasis Therapeutics Provides Update on Development of PTI-801 52
03/12/2018: Proteostasis Therapeutics Announces FDA Grants Breakthrough Therapy Designation for PTI-428 in Cystic Fibrosis 53
01/08/2018: Proteostasis Proprietary Triple Combination Therapy Study Protocol Receives Endorsement and High Strategic Fit Score from the Largest Cystic Fibrosis Patient Advocacy Groups in the U.S. and Europe 54
Product Approvals 55
Apr 04, 2018: Proteostasis Therapeutics Receives FDA Fast Track Designation for Triple Combination Program in Patients with Cystic Fibrosis 55
Mar 14, 2018: Proteostasis Therapeutics Announces FDA Grants Orphan Drug Designation for PTI-428 in Cystic Fibrosis 56
Jun 23, 2017: Proteostasis Therapeutics Files Investigational New Drug Application for PTI-808, Cystic Fibrosis Potentiator 57
Clinical Trials 58
Dec 11, 2017: Proteostasis Therapeutics Announces Positive Clinical Results from Studies of PTI-428 in Healthy Volunteers and Patients with Cystic Fibrosis 58
Dec 11, 2017: Proteostasis Therapeutics Announces Positive Clinical Results from Studies of PTI-808 in Healthy Volunteers and Patients with Cystic Fibrosis 59
Jul 31, 2017: Proteostasis Therapeutics Provides Update on Development of PTI-808 60
Jun 29, 2017: Proteostasis Therapeutics Reports Preliminary Data from Phase 1 Study of PTI-428 in Patients with Cystic Fibrosis 61
Jun 07, 2017: Proteostasis Therapeutics Announces Clinical and Regulatory Progress Across Pipeline Programs 63
Jun 07, 2017: Proteostasis Therapeutics Announces Clinical Development Update on Cystic Fibrosis Drug Candidate PTI-801 64
Jun 07, 2017: Proteostasis Therapeutics Announces Update on Phase 1 Trial of PTI-808, CFTR potentiator 65
Appendix 66
Methodology 66
About GlobalData 66
Contact Us 66
Disclaimer 66

List of Tables
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Proteostasis Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Proteostasis Therapeutics Raises USD37 Million in Series B Financing 12
Proteostasis Therapeutics Raises USD22 Million in Venture Financing 14
Proteostasis Therapeutics Raises Additional USD2 Million in Venture Financing 15
Proteostasis Therapeutics Raises USD3 Million in Venture Financing 16
Basilea Pharma Enters into Agreement with Adult Brain Tumor Consortium 17
Basilea Pharmaceutica International Enters into Agreement with Biomedical Advanced Research and Development Authority 18
Proteostasis Therapeutics Amends Research Agreement with Astellas Pharma 19
Proteostasis Therapeutics Extends Co-Development Agreement With Cystic Fibrosis Foundation Therapeutics 20
Proteostasis Therapeutics Enters Into Co-Development Agreement With Scripps Research Institute 21
Proteostasis Therapeutics Enters into Co-Development Agreement with Cystic Fibrosis Foundation Therapeutics 22
Grupo Biotoscana Enters into Licensing Agreement with Basilea Pharma 23
Basilea Pharma Enters into Licensing Agreement with Asahi Kasei Pharma 24
Hikma Pharma Extends its Distribution Agreement with Basilea Pharma 25
Basilea Pharmaceutical Amends Terms of Licensing Agreement with Stiefel Labs for Toctino 26
Dotmatics Enters Into Licensing Agreement With Basilea Pharma For Pre-Clinical Research Informatics 27
Proteostasis Therapeutics Prices Public Offering of Shares for USD74.3 Million 28
Proteostasis Therapeutics to Raise USD50 Million in Public Offering of Shares 30
Proteostasis Therapeutics Withdraws Public Offering of Shares for USD65.6 Million 31
Proteostasis Therapeutics Raises USD46 Million in Public Offering of Shares 33
Proteostasis Therapeutics Raises USD65 Million in Public Offering of Shares 35
Proteostasis Therapeutics Inc, Key Competitors 37
Proteostasis Therapeutics Inc, Key Employees 38

List of Figures
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9